Peter S. Sever

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 677 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott et al. · The Lancet Diabetes & Endocrinology · 2017 · 596 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Cognitive Function in a Randomized Trial of Evolocumab

Robert P. Giugliano, François Mach, Kenton H. Zavitz et al. · New England Journal of Medicine · 2017 · 482 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Robert P. Giugliano, Terje R. Pedersen, Jeffrey L. Saver et al. · Stroke · 2020 · 182 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

Gregg C. Fonarow, Anthony Keech, Terje R. Pedersen et al. · JAMA Cardiology · 2017 · 149 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17